Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness

Wenzhong Du†, Xing Liu†, Lingchao Chen†, Zhijin Dou, Xuhui Lei, Liang Chang, Jinquan Cai, Yuqiong Cui, Dongbo Yang, Ying Sun, Yongli Li, and Chuanlu Jiang

Department of Neurosurgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China (W.D., X.L., Z.D., X.L., L.C., J.C., Y.C., D.Y., Y.S., Y.L., C.J.); Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China (L.C.)

Corresponding Author: Chuanlu Jiang, PhD, Department of Neurosurgery, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangong, Harbin, Heilongjiang Province 150086, P.R. China (jcl16688@163.com).

†Wenzhong Du, Xing Liu and Lingchao Chen contributed equally to this paper.

Background. Few studies have associated microRNAs (miRNAs) with the hedgehog (Hh) pathway. Here, we investigated whether targeting smoothened (SMO) with miR-326 would affect glioma biological behavior and stemness.

Methods. To investigate the expression of SMO and miR-326 in glioma specimens and cell lines, we utilized quantitative real-time (qRT)-PCR, Western blot, immunohistochemistry, and fluorescence in situ hybridization. The luciferase reporter assay was used to verify the relationship between SMO and miR-326. We performed cell counting kit-8, transwell, and flow cytometric assays using annexin-V labeling to detect changes after transfection with siRNA against SMO or miR-326. qRT-PCR assays, neurosphere formation, and immunofluorescence were utilized to detect the modification of self-renewal and stemness in U251 tumor stem cells. A U251-implanted intracranial model was used to study the effect of miR-326 on tumor volume and SMO suppression efficacy.

Results. SMO was upregulated in gliomas and was associated with tumor grade and survival period. SMO inhibition suppressed the biological behaviors of glioma cells. SMO expression was inversely correlated with miR-326 and was identified as a novel direct target of miR-326. miR-326 overexpression not only repressed SMO and downstream genes but also decreased the activity of the Hh pathway. Moreover, miR-326 overexpression decreased self-renewal and stemness and partially prompted differentiation in U251 tumor stem cells. In turn, the inhibition of Hh partially elevated miR-326 expression. Intracranial tumorigenicity induced by the transfection of miR-326 was reduced and was partially mediated by the decreased SMO expression.

Conclusions. This work suggests a possible molecular mechanism of the miR-326/SMO axis, which can be a potential alternative therapeutic pathway for gliomas.

Keywords: glioma, hedgehog, miRNA, SMO, stemness.

Received 27 January 2014; accepted 29 July 2014

© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
3′-untranslated regions of their messenger RNA (mRNA). They have been identified as a new type of gene expression regulator that targets mRNAs for translational repression or degradation. Increasing evidence has strongly implicated the involvement of miRNAs in carcinogenesis, including pancreas, breast, colon and lung cancers, leukemia, prostate carcinoma, and glioblastoma. Dysregulated miRNAs may function as oncogenes or tumor suppressor genes. In addition, miRNAs play important roles in diverse biological processes, including development, differentiation, stem cell maintenance, and cell identity.

Little is known, however, about the regulation of miRNAs and their interaction with the major signaling pathways in gliomas, especially with respect to Hh signaling.

In this study, we aimed to explore the expression and function of SMO in gliomas and its relationship with miR-326. For the first time, we showed that miR-326 affected the activity of Hh signaling pathway mediated by SMO and also regulated the self-renewal ability and stemness and partially prompted differentiation in glioma stem cells. Moreover, inhibition of the Hh pathway partially increased miR-326 expression. These results further confirmed that the feedback loop between miR-326 and the SMO oncogene might be considered an alternative for multiple treatments of gliomas by regulating the Hh/SMO/GLI1 pathway.

Materials and Methods

Tissue Samples and Clinical Data

Informed consent was obtained for the application of human glioma tissue samples from adult patients who received a glioma diagnosis at the Second Affiliated Hospital of Harbin Medical University. Freshly resected tissue samples were immediately frozen in liquid nitrogen for subsequent total RNA extraction. All samples were histologically classified and graded according to WHO guidelines by clinical pathologists and included 16 grade I-II tumors, 13 grade III tumors, and 16 grade IV tumors (Table 1). Additionally, 5 normal adult brain tissue specimens were used as controls from patients with severe traumatic brain injury who required surgery (with informed consent). Fifty paraffin-embedded glioma specimens with various grade and clinical data were collected for subsequent experimentation from the Second Affiliated Hospital of Harbin Medical University from January 2008 through June 2009. This study was approved by the hospital institutional review board, and written informed consent was obtained from all patients.

Table 1. Clinicopathological parameters of 45 glioma samples from the Second Affiliated Hospital of Harbin Medical University

<table>
<thead>
<tr>
<th>No.</th>
<th>Age</th>
<th>Sex</th>
<th>Pathology (WHO)</th>
<th>No.</th>
<th>Age</th>
<th>Sex</th>
<th>Pathology (WHO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>31</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td>24</td>
<td>45</td>
<td>Male</td>
<td>Astrocytoma II</td>
</tr>
<tr>
<td>02</td>
<td>54</td>
<td>Male</td>
<td>Glioblastoma IV</td>
<td>25</td>
<td>34</td>
<td>Female</td>
<td>Astrocytoma I</td>
</tr>
<tr>
<td>03</td>
<td>36</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td>26</td>
<td>49</td>
<td>Female</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>04</td>
<td>45</td>
<td>Male</td>
<td>Astrocytoma III</td>
<td>27</td>
<td>47</td>
<td>Male</td>
<td>Oligodendroglioma II</td>
</tr>
<tr>
<td>05</td>
<td>51</td>
<td>Male</td>
<td>Glioblastoma IV</td>
<td>28</td>
<td>50</td>
<td>Male</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>06</td>
<td>48</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td>29</td>
<td>43</td>
<td>Male</td>
<td>Astrocytoma II</td>
</tr>
<tr>
<td>07</td>
<td>63</td>
<td>Female</td>
<td>Astrocytoma III</td>
<td>30</td>
<td>31</td>
<td>Male</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>08</td>
<td>50</td>
<td>Female</td>
<td>Glioblastoma IV</td>
<td>31</td>
<td>52</td>
<td>Female</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>09</td>
<td>59</td>
<td>Male</td>
<td>Glioblastoma IV</td>
<td>32</td>
<td>41</td>
<td>Male</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>10</td>
<td>40</td>
<td>Male</td>
<td>Astrocytoma III</td>
<td>33</td>
<td>50</td>
<td>Female</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>11</td>
<td>45</td>
<td>Male</td>
<td>Oligodendroglioma II</td>
<td>34</td>
<td>56</td>
<td>Female</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>12</td>
<td>52</td>
<td>Male</td>
<td>Astrocytoma II</td>
<td>35</td>
<td>59</td>
<td>Male</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>13</td>
<td>6</td>
<td>Male</td>
<td>Glioblastoma IV</td>
<td>36</td>
<td>58</td>
<td>Female</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>14</td>
<td>47</td>
<td>Male</td>
<td>Glioblastoma IV</td>
<td>37</td>
<td>20</td>
<td>Male</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>15</td>
<td>9</td>
<td>Female</td>
<td>Astrocytoma I</td>
<td>38</td>
<td>49</td>
<td>Female</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>16</td>
<td>44</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td>39</td>
<td>40</td>
<td>Male</td>
<td>Astrocytoma I</td>
</tr>
<tr>
<td>17</td>
<td>49</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td>40</td>
<td>15</td>
<td>Female</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>18</td>
<td>42</td>
<td>Male</td>
<td>Oligodendroglioma II</td>
<td>41</td>
<td>31</td>
<td>Male</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>19</td>
<td>8</td>
<td>Male</td>
<td>Astrocytoma III</td>
<td>42</td>
<td>36</td>
<td>Male</td>
<td>Glioblastoma IV</td>
</tr>
<tr>
<td>20</td>
<td>9</td>
<td>Male</td>
<td>Astrocytoma II</td>
<td>43</td>
<td>40</td>
<td>Male</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>21</td>
<td>45</td>
<td>Female</td>
<td>Astrocytoma III</td>
<td>44</td>
<td>40</td>
<td>Male</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>22</td>
<td>42</td>
<td>Female</td>
<td>Astrocytoma III</td>
<td>45</td>
<td>63</td>
<td>Female</td>
<td>Astrocytoma III</td>
</tr>
<tr>
<td>23</td>
<td>28</td>
<td>Female</td>
<td>Astrocytoma II</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: WHO, World Health Organization.
supplemented with B-27,20 ng/ml basic fibroblast growth factor and 20 ng/ml epidermal growth factor (EGF).

Oligonucleotides, Sonic Hedgehog, and Cyclopamine Treatments

miR-326 mimics, miR-326 inhibitor, miR-scramble (miR-Scr) and SMO siRNA (siSMO) were synthesized and purified using high-performance liquid chromatography (GenePharma; see Supplementary data for detailed sequences). Cells were transfected with miR-326 mimics, miR-326 inhibitor, or SMO siRNA (200 pmol each) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells transfected with miR-Scr were used as a control. Commercial N-Shh (R&D Systems) was used at 0.5 μM. Cyclopamine (Sigma) was used at 10 μM. Cells were starved in 0.5% serum (instead of the usual 10% routinely used for standard growth after medication) for 12 hours before medication and were continued in culture for an additional 48 hours.

RNA Extraction and Complementary DNA Synthesis

Total RNA was extracted using TRizol reagent (Invitrogen). The first strand complementary DNAs (cDNAs) were synthesized using the PrimeScript RT reagents Kit (Perfect Real Time, Takara) according to the manufacturer's instructions. The reverse transcription reaction was carried out at 37 °C for 15 minutes and was then inactivated at 85 °C for 5 seconds.

Quantitative Real-time Polymerase Chain Reaction

To investigate the expression of miRNAs, SMO, and other stemness markers in glioma samples and cell lines, quantitative real-time (qRT)-PCR was performed in triplicate in a LightCycler2.0 (Roche Diagnostics) and normalized to glyceraldehyde 3-phosphatedehydrogenase (GAPDH) and U6 as endogenous controls. The qRT-PCR data were analyzed using the 2^−ΔΔCt method. (see Supplementary material for qRT-PCR primers.)

In-situ Hybridization for miRNA

To study the spatial and temporal expression of miRNAs with high sensitivity and resolution, miRNA fluorescence in-situ hybridization (FISH) was performed according to manufacturer’s protocol.

Proliferation Assay

The cell count kit-8 assay was used to quantify the human glioma cell viability, as previously described. Each experiment was performed in triplicate. All proliferation assays were repeated as independent experiments at least twice.

In Vitro Invasion Assays

Transwell membranes coated with Matrigel (BD Biosciences) were used to quantify in vitro glioma cell invasion, as previously described. Fold migration was calculated relative to a blank control. The data represent mean ± standard error (SE) of 3 independent experiments.

Evaluation of Cell Apoptosis

Apoptosis was quantified using annexin V labeling after transfection for 48 hours. The cells were resuspended in binding buffer. Then, 10 μl of FITC annexin V and 5 μl of propidium iodide (BD Pharmingen) were added and incubated for 15 minutes. The stained cells were analyzed by flow cytometry (FACSCanto II, BD Biosciences).

Luciferase Reporter Assay

To determine the Hh pathway transcriptional activity, a reporter containing 8 directly repeated copies of a consensus GLI binding site (8x-GLI) downstream of the luciferase gene was used. The plasmids were transfected into cells treated with miR-326 mimics or miR-Scr with cotransfection of an expression construct containing the entire SMO coding sequence without its 3′-UTR fragment. In addition, the SMO 3′UTR-Luc reporter and the mutant reporter were obtained from Promega (see Supplementary material for detailed information).

Western Blot Assay

Western blot assays were performed as previously described. Primary antibodies included anti-SMO (1:1000 dilution; Abcam), anti-GLI1 (1:1000 dilution; CST), anti-CyclinD1, anti-N-MYC(1:300), and anti-GAPDH (1:1000 dilution; Santa Cruz Biotechnology). Following incubation with the horseradish peroxidase-labeled secondary antibody (Introvigen), protein bands were detected on Fujifilm Las-4000.

Immunofluorescence and Immunohistochemistry

Immunofluorescence and immunohistochemistry (IHC) assays were performed as previously described. These assays used antibodies against CD133, nestin, GLI1, gli fibrillary acidic protein (GFAP; 1:200 dilution; Bioss Inc.) and SMO (1:100 dilution; Santa Cruz Biotechnology). Immunofluorescence staining was visualized using anti-mouse Alexa Fluor 488 (Molecular Probes) or anti-rabbit–rhodamine antibody conjugates (Dianova).Nuclei were counterstained using 4′,6-diamidino-2-phenylindole (DAPI; Sigma). The slides were analyzed by confocal laser scanning microscopy (Olympus FV1000 laser scanning microscope). IHC scores were calculated using a semiquantitative 5-category grading system.

Nude Mouse Tumor Intracranial Model and miR-326 Treatment

U251 cells that were cotransduced with miR-326 mimics/scramble oligonucleotide, and luciferase lentivirus were injected intracranially into 5-week–old BALB/c-nude mice. After 20 days, tumors were measured by fluorescent images of whole mice using an IVIS Lumina Imaging System (Xenogen). Portions of the tumor tissues were used to measure miR-326 by qRT-PCR and SMO by Western blot. Cryosections (4 mm) were stained with hematoxylin and eosin (H&E) and used for IHC. These procedures were performed following approval by the Harbin Medical University Institutional Animal Care and Use Committee.
Statistical Analyses

Statistics were performed using the SPSS Graduate Pack, version 11.0 statistical software (SPSS). Descriptive statistics, including mean, SE, and 1-way ANOVA, were used to determine significant differences. The survival curves were analyzed using the log-rank test employing Prism GraphPad software. Statistical significance was assumed at a value of \( P < .05 \).

Results

SMO Was Upregulated in Glioma Samples and Cell Lines and Was Associated With Tumor Grade and Poor Survival

The result of qRT-PCR and Western blot showed that SMO was highly expressed in high-grade gliomas compared with low-grade gliomas and normal brain tissues (Fig. 1A and B). This result was consistent with the data from other databases (Supplementary material, Fig. S2A–C). Furthermore, SMO expression was also detected in 4 glioma cell lines (U251, T98G, U87, and SHG44) and one glioma stem cell line (U251-TSC). Compared with the human oligodendroglial cell line (Olig), SMO was highly expressed in all glioma cell lines except for U87 (Fig. 1C). Subsequently, a retrospective analysis of the clinical outcome of our patients and other databases revealed that increased SMO correlated with poor survival (Fig. 1D and Supplementary material, Fig. S2D–I) (*\( P < .05 \)).

SMO Knockdown Suppressed the Biological Behaviors of Glioma Cells

Given that SMO is a crucial regulator of the Hh pathway and was highly expressed in gliomas, we assessed its importance on the tumorigenic properties of glioma cells, including proliferation, invasion, and apoptosis. In our study, we found that siSMO significantly reduced the expression of SMO at the mRNA levels after transfecting SMO siRNA into glioma cell lines (U251 and T98G) and the TSC line (Supplementary material, Fig. S3A). Meanwhile, siSMO also decreased cell proliferation and the number of invasive glioma cells and significantly increased apoptosis compared with the control group (Fig. 2A–C). Together, these data showed that the tumorigenic properties of glioma cells, specifically proliferation, invasion, and apoptosis, were influenced by SMO inhibition.

SMO Was a Direct Target of miR-326

miRNA target searches using Targetscan and Miranda (http://www.targetscan.org/ and http://www.microrna.org/) confirmed that the seed sequence of miR-326 matched 2 sites of the 3′UTR of the SMO gene (Fig. 2D). To investigate whether SMO is a functional target of miR-326, we assessed its mRNA and protein levels after the transfection of miR-326 mimics. First, qRT-PCR was used to evaluate the transfection efficiency (Supplementary material, Fig. S3B). Next, SMO mRNA level was detected without significant change following transfection with
scramble, miR-326 mimics, or miR-326 inhibitor (Supplementary material, Fig. S3C). Western blot indicated decreased levels of SMO protein in the miR-326 mimics-transfected cells compared with the scramble (Fig. 2E). However, the miR-326 inhibitor did not show a significant effect on SMO protein expression (data not shown), which may be caused by the low miR-326 expression in gliomas. To further confirm whether SMO was a direct target of miR-326, we transfected pGL3-WT-SMO-3′UTR or pGL3-MUT-SMO-3′UTR dual-luciferase reporter plasmids with miR-326 mimic or scramble into HEK293T cells for 48 hours, followed by measurement of luciferase activity. Our results showed that transfection with miR-326 reduced the luciferase activity significantly compared with the scramble group. However, the luciferase activity in the mutant construct did not show significant differences (Fig. 2F). These data indicated that miR-326 directly modulated SMO expression by binding to the 3′UTR.

SMO Expression Was Inversely Correlated With miR-326

Several studies have reported that miR-326 is decreased in gliomas and has a therapeutic potential against brain tumors. To further investigate whether reduced miR-326 expression correlates with SMO expression levels in gliomas, patient specimens were used to examine its expression by IHC and FISH. The results suggested that high-grade gliomas contain comparatively higher SMO expression and lower miR-326 levels than low-grade specimens (Fig. 3A). Spearman’s correlation analysis demonstrated that SMO in tumor tissues was inversely correlated with miR-326 expression (Fig. 3B). Furthermore, we examined miR-326 expression in our glioma cell lines by qRT-PCR (Fig. 3C). Combined with the relative expression of SMO, a linear inverse correlation was observed, verifying that SMO expression was inversely correlated with miR-326 (Fig. 3D).

Upregulation of miR-326 Affected the Hh Signaling Pathway and Rescued the Protumor Effects of SMO

After confirming the relationship between SMO and miR-326, we intended to test the effect of upregulated miR-326 on Hh activity. We introduced an expression construct containing the entire SMO coding sequence without its 3′-UTR fragment into miR-326- or miR-Scr-overexpressing cells, followed by cotransfection of the 8×GLI reporter downstream of the luciferase gene to determine the Hh pathway transcriptional activity. Our results showed that miR-326 upregulation reduced the Hh activity by more than 30% (Fig. 4A; P < .05). Subsequently, we investigated whether GLI1 expression was impacted by miR-326 upregulation with or without recombinant Shh-N-Terminus. qRT-PCR showed that miR-326 upregulation significantly reduced GLI1 expression (Fig. 4B and C). Moreover, Western blot assays showed that miR-326 upregulation decreased the expression of GLI1 and its downstream target proteins, including N-myc and CyclinD1, in glioma and tumor stem cells (Fig. 4D). To determine whether the protumor effects of SMO can be rescued by the upregulation of miR-326, Western blot assays were used primarily to evaluate the effect on protein levels. The results showed that miR-326 upregulation significantly decreased SMO expression (Fig. 4E and F). In addition, invasion, CCK-8, and apoptosis assays were adopted to further...
verify that miR-326 upregulation partially rescued SMO-dependent effects on glioma proliferation, invasion, and apoptosis (Fig. 4G–I).

miR-326 Upregulation Regulated the Ability of Self-renewal and Stemness and Prompted Differentiation in Glioma Stem Cells

Evidence has already demonstrated that Hh signaling regulates stemness and self-renewal capacity in CD133+ glioma cancer stem cells.5,33 We further examined the role of miR-326 in the differentiation, stemness, and self-renewal of CD133+ glioma tumor stem cells. First, we examined the effects of miR-326 on neurosphere formation in U251 TSCs, which was thought to be a characteristic of self-renewal in the glioma stem-like cell subpopulation. We observed a significant decrease in the number and volume of the neurospheres transfected with miR-326 compared with scramble, suggesting that miR-326 plays a role in glioma stem cells, at least in part, by blocking the SMO-mediated pathways involved in stem cell renewal (Fig. 5A). Subsequently, qRT-PCR and Western blot assays showed that miR-326 upregulation decreased the expression of specific stemness markers, including Bmi-1, Oct-4, Sox2, Nanog, and Shh (Fig. 5B and C). Last, to further investigate whether the ability of stemness and differentiation were influenced by miR-326 upregulation, immunofluorescence was used to examine the expression of markers of stem cells (nestin) and glial cells (GFAP) in U251-TSCs. The results suggested that miR-326 upregulation significantly decreased the percentage of nestin-positive cells and enhanced GFAP expression in glial differentiation (Fig. 5D and E). All of the above data suggest that the glioma tumor stem cell properties can be partly regulated by changes in miR-326.

Inhibition of the Hh Pathway Partially Restored miR-326 Expression

After confirming that SMO was a direct target of miR-326 that can be downregulated by miR-326 overexpression, we questioned whether blocking the Hh pathway would influence miR-326 expression. Cyclopamine was used to block the Hh signaling pathway in U251, T98G, and U251-TSC cells for 48 hours, and qRT-PCR indicated that miR-326 expression increased 1.6-multiples, 1.9-multiples, and 2.3-multiples, respectively, compared with glioma cell lines exposed to dimethyl sulfoxide (P < .05; Fig. 5F). These data suggested that miR-326 was partly regulated by Hh/Smo activity in some ways.

miR-326 Overexpression Inhibited Tumor Growth in Vivo and Prolonged Survival

Because miR-326 upregulation decreased SMO expression and the activity of the Hh pathway in gliomas in vitro, we evaluated...
its antiglioma effects in vivo. The results showed that miR-326 mimic-treated cells displayed a marked reduction in tumor size (Fig. 6A). To further verify tumor growth in both groups visually, H&E-stained coronal brain sections were used to show representative tumor xenografts (Fig. 6B). Subsequently, qRT-PCR analysis confirmed that miR-326 expression was increased in the tumor compared with scramble controls (Fig. 6C). Moreover, miR-326 mimic-treated U251 cells decreased the expression of SMO, GLI1, and nestin and increased the expression of GFAP (Fig. 6D and Supplementary material, Fig. S4). These data indicated that miR-326 overexpression in vivo functioned similarly to that in vitro. To further evaluate the therapeutic effect of miR-326 on nude mice, the survival period of each group (n = 7/group) was analyzed by Kaplan–Meier curve. The miR-326 mimic-treated group showed a significant improvement in survival compared with the control group (P < .05) (Fig. 6E) until the end of the observation period.

**Discussion**

Although there have already been several studies related to miRNA and its functional significance, little is known regarding miRNA interactions with the Hh pathway in gliomas. M Ehtesham et al. have provided evidence that the Hh pathway was activated in a ligand-dependent manner, with a strict requirement for exogenous Hh ligand in glioma progenitor cells. Our previous study also reported that the Hh pathway is abnormally activated in malignant gliomas and can be considered an
In this way, secreted Hh ligands binds to PTCH1 and blocks the inhibition of SMO. SMO activation then leads to changes in gene expression through the action of GLI proteins. In this study, we emphasized the role of SMO in gliomas. We found that SMO was upregulated in glioma samples and cell lines and associated with tumor grade and poor survival. SMO, a 7-transmembrane protein that transduces the Hh signal across the plasma membrane has been demonstrated to be activated in many cancers, including basal cell carcinoma, thyroid cancer, pancreatic carcinoma, leukemia, medulloblastoma, non-small cell lung cancer and glioblastoma. The inhibition of SMO can suppress tumor cell growth and invasion, induce apoptosis, enhance sensitivity to chemotherapy, and prolong the survival of established tumor xenografts in several tumors.43,44 We also found that SMO inhibition affected diverse biological processes in gliomas. In our study, we selected 2 glioma cell lines (T98G and U251) and a glioma stem cell line (U251-TSC) as our experimental subjects because of their relatively high SMO expression compared with other cell lines. The inhibition of SMO by its specific siRNA suppressed the proliferation and invasion and induced the apoptosis of glioma cells. These results were similar to those of previous studies, which used GBM specimens instead of glioma cell lines.43 Eimer et al demonstrated that cycloamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.44 Furthermore, Takezaki et al reported that the Hh pathway is indispensable for glioma-initiating cell proliferation and tumorigenesis. The Hh signaling inhibitors prevented glioma-initiating cell proliferation, whereas signaling inhibitors for Notch or Wnt did not. These data showed that Hh signaling plays an important role in gliomas and can be targeted as an alternative potential therapeutic pathway.

miR-326 has been reported as a tumor suppressor miRNA in various tumor types, including gliomas.48,49 In addition, several miR-326 targets have been identified, including Notch-1, Notch-2, PKM2, and NOB1 in gliomas.30-32 However, in our study, combining bioinformatics prediction, functional experiments in vitro, and luciferase reporter assays, SMO was verified as a direct target of miR-326. This result raised the appealing prospect that miR-326 has multiple targets that could be involved in various pathways. Subsequently, a significant inverse correlation was verified between miR-326 expression and SMO expression in glioma tissues and cell lines, further confirming that SMO is an endogenous target of miR-326. Importantly, upregulation not only inhibited the activity of the Hh pathway but also reduced the expression of additional Hh signaling components, including GLI1, N-myc, and CyclinD1. In addition, transfection with miR-326 mimics partially rescued the protumor effects of SMO with regard to invasion, proliferation, and apoptosis in glioma cells. All of the above data further demonstrated the biological relevance of the miR-326/SMO relationship.

Santini and Clement have reported that Hh signaling is closely related to the stemness and self-renewal of cancer stem cells and glioma stem cells.50 In this study, we found that miR-326 upregulation also reduced the volume and number of tumor spheres and decreased the expression of stem cell-associated proteins Bmi1, Nanog, Shh, Oct4, and Sox2 in CD133+ glioma cells. Moreover, miR-326 upregulation...
significantly decreased the fraction of nestin-expressing stem cells, increased the fraction of GFAP-expressing cells, and prompted differentiation, suggesting its direct inhibition of Hh/GLI1 signaling and stemness through targeting SMO in CD133+ cells.

Interestingly, when SMO was inhibited by its specific inhibitor, the expression of miR-326 was also elevated. This might have been caused by epigenetic abnormalities, including changes in DNA methylation or histone modifications. Thus, both miR-326 and SMO were partly regulated by each other as a feedback loop. Furthermore, the transfection of glioma cells with miR-326 mimics in the orthotopic model reduced tumorigenicity, which might have been mediated by SMO inhibition. Importantly, miR-326 upregulation prolonged the survival of nude mice.

In summary, we found that the upregulation of miR-326, as a suppressor miRNA in gliomas, inhibited proliferation, induced apoptosis, and decreased the stemness of gliomas by targeting SMO through the Hh pathway. Furthermore, SMO inhibition partly restored miR-326 expression, suggesting that the miR-326/SMO feedback loop could be considered an alternative therapy for gliomas in the future.

Supplementary Material
Supplementary material is available online at Neuro-Oncology (http://neuro-oncology.oxfordjournals.org/).

Funding
This work was supported by the National High Technology Research and Development Program 863 (2012AA02A508), China National Natural Scientific Fund (81372700), China Postdoctoral Science Foundation (2013M531121), Shanghai Postdoctoral Science Foundation.

Fig. 6. Overexpression of miR-326 inhibited tumor growth in vivo and prolonged survival. (A) Luminescence imaging for miR-326–treated U251-luc tumors versus scramble-treated controls. (B) H&E-stained coronal brain sections showing representative tumor xenografts. (C) miR-326 and SMO expression in an intracranial graft assessed by RT-PCR and Western blot. (D) SMO and GLI1 expression after transfecting miR-326 in tumor sections following IHC analysis (*P < .05; the bars represent 25 μm). (E) Kaplan-Meier survival curves indicating that mice transfected with miR-326 showed a significantly better outcome than the miR-Scr-treated group (*P < .05).
(13R21411300), China Postdoctoral Science special Foundation funded project (2014T70390).

Acknowledgments
We thank professor X.Ban for the technical assistance. We also thank Dr. Hongjun Wang for providing the database information.

Conflict of interest statement. None declared.

References


